|
Melanoma treatment
|
Life-months over all available follow-up
|
Projected life-months for all drugs up to 7 yearsb
|
|---|
|
Life-monthsa
|
Weibull
|
Exponential
|
Gompertz
|
Log-normal
|
|---|
|
Ipilimumab
|
28.52
|
N/A
|
N/A
|
N/A
|
N/A
|
|
Dabrafenib
|
21.47
|
26.51c
|
30.03
|
26.50
|
30.52
|
|
Trametinib
|
7.32
|
21.25c
|
26.53
|
16.94
|
36.69
|
|
Vemurafenib
|
13.00
|
14.28c
|
20.65
|
13.69
|
18.10
|
|
Dabrafenib + trametinib
|
16.78
|
24.55c
|
36.75
|
21.88
|
33.12
|
-
aLife-months were calculated by the area under the curve of the Kaplan–Meier curves of overall survival for different drugs
-
bParametric survival modeling was used to extrapolate the survival probabilities of dabrafenib, trametinib, vemurafenib, and dabrafenib + trametinib. Weibull model was used as the primary model (results denoted with c). Other parametric models (exponential, Gompertz, and log-normal) were used as sensitivity analysis
